Papel de los polimorfismos -238 y -308 del promotor del factor de necrosis tumoral alfa en la patogenia y respuesta al tratamiento anti- factor de necrosis tumoral alfa en artritis reumatoide

Rheumatoid arthritis (RA) is a systemic autoimmune disease that affects 0.8% of the world population, it affects the synovial membrane of joints and the clinical presentation encompasses a wide spectrum, ranging from a mild to a severe and erosive disease that causes joint and cartilage destruction...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Llanos M,Carolina, Soto S,Lilian, Sabugo S,Francisca, Bastías Ch,M José, Salazar A,Lorena, Aguillón G,Juan C, Cuchacovich T,Miguel
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2005
Materias:	Arthritis, rheumatoid Genotype Tumor necrosis factor-alpha
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872005000900014
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872005000900014
record_format	dspace
spelling	oai:scielo:S0034-988720050009000142005-11-09Papel de los polimorfismos -238 y -308 del promotor del factor de necrosis tumoral alfa en la patogenia y respuesta al tratamiento anti- factor de necrosis tumoral alfa en artritis reumatoideLlanos M,CarolinaSoto S,LilianSabugo S,FranciscaBastías Ch,M JoséSalazar A,LorenaAguillón G,Juan CCuchacovich T,Miguel Arthritis, rheumatoid Genotype Tumor necrosis factor-alpha Rheumatoid arthritis (RA) is a systemic autoimmune disease that affects 0.8% of the world population, it affects the synovial membrane of joints and the clinical presentation encompasses a wide spectrum, ranging from a mild to a severe and erosive disease that causes joint and cartilage destruction which finally provokes irreversible structural damage and patient disability. In the last years, there have been important advances in the pathogenesis of this disease, the efforts have been concentrated on pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFalpha). This protein guides numerous events in the synovial and systemic inflammatory process and is encoded in the Major Histocompability Complex (MHC), one of the most polymorphic of the genome. Polymorphisms affecting the TNFalpha gene and its regulatory regions are associated with RA prevalence and course. There is a possible association between these polymorphisms and the clinical response to the use of monoclonal antibodies anti-TNFalpha. The possibility that the determination of genotypes -238 and -308 may have prognostic and therapeutic consequences is debated nowadays (Rev Méd Chile 2005; 133: 1089-95).info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.133 n.9 20052005-09-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872005000900014es10.4067/S0034-98872005000900014
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Arthritis, rheumatoid Genotype Tumor necrosis factor-alpha
spellingShingle	Arthritis, rheumatoid Genotype Tumor necrosis factor-alpha Llanos M,Carolina Soto S,Lilian Sabugo S,Francisca Bastías Ch,M José Salazar A,Lorena Aguillón G,Juan C Cuchacovich T,Miguel Papel de los polimorfismos -238 y -308 del promotor del factor de necrosis tumoral alfa en la patogenia y respuesta al tratamiento anti- factor de necrosis tumoral alfa en artritis reumatoide
description	Rheumatoid arthritis (RA) is a systemic autoimmune disease that affects 0.8% of the world population, it affects the synovial membrane of joints and the clinical presentation encompasses a wide spectrum, ranging from a mild to a severe and erosive disease that causes joint and cartilage destruction which finally provokes irreversible structural damage and patient disability. In the last years, there have been important advances in the pathogenesis of this disease, the efforts have been concentrated on pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFalpha). This protein guides numerous events in the synovial and systemic inflammatory process and is encoded in the Major Histocompability Complex (MHC), one of the most polymorphic of the genome. Polymorphisms affecting the TNFalpha gene and its regulatory regions are associated with RA prevalence and course. There is a possible association between these polymorphisms and the clinical response to the use of monoclonal antibodies anti-TNFalpha. The possibility that the determination of genotypes -238 and -308 may have prognostic and therapeutic consequences is debated nowadays (Rev Méd Chile 2005; 133: 1089-95).
author	Llanos M,Carolina Soto S,Lilian Sabugo S,Francisca Bastías Ch,M José Salazar A,Lorena Aguillón G,Juan C Cuchacovich T,Miguel
author_facet	Llanos M,Carolina Soto S,Lilian Sabugo S,Francisca Bastías Ch,M José Salazar A,Lorena Aguillón G,Juan C Cuchacovich T,Miguel
author_sort	Llanos M,Carolina
title	Papel de los polimorfismos -238 y -308 del promotor del factor de necrosis tumoral alfa en la patogenia y respuesta al tratamiento anti- factor de necrosis tumoral alfa en artritis reumatoide
title_short	Papel de los polimorfismos -238 y -308 del promotor del factor de necrosis tumoral alfa en la patogenia y respuesta al tratamiento anti- factor de necrosis tumoral alfa en artritis reumatoide
title_full	Papel de los polimorfismos -238 y -308 del promotor del factor de necrosis tumoral alfa en la patogenia y respuesta al tratamiento anti- factor de necrosis tumoral alfa en artritis reumatoide
title_fullStr	Papel de los polimorfismos -238 y -308 del promotor del factor de necrosis tumoral alfa en la patogenia y respuesta al tratamiento anti- factor de necrosis tumoral alfa en artritis reumatoide
title_full_unstemmed	Papel de los polimorfismos -238 y -308 del promotor del factor de necrosis tumoral alfa en la patogenia y respuesta al tratamiento anti- factor de necrosis tumoral alfa en artritis reumatoide
title_sort	papel de los polimorfismos -238 y -308 del promotor del factor de necrosis tumoral alfa en la patogenia y respuesta al tratamiento anti- factor de necrosis tumoral alfa en artritis reumatoide
publisher	Sociedad Médica de Santiago
publishDate	2005
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872005000900014
work_keys_str_mv	AT llanosmcarolina papeldelospolimorfismos238y308delpromotordelfactordenecrosistumoralalfaenlapatogeniayrespuestaaltratamientoantifactordenecrosistumoralalfaenartritisreumatoide AT sotoslilian papeldelospolimorfismos238y308delpromotordelfactordenecrosistumoralalfaenlapatogeniayrespuestaaltratamientoantifactordenecrosistumoralalfaenartritisreumatoide AT sabugosfrancisca papeldelospolimorfismos238y308delpromotordelfactordenecrosistumoralalfaenlapatogeniayrespuestaaltratamientoantifactordenecrosistumoralalfaenartritisreumatoide AT bastiaschmjose papeldelospolimorfismos238y308delpromotordelfactordenecrosistumoralalfaenlapatogeniayrespuestaaltratamientoantifactordenecrosistumoralalfaenartritisreumatoide AT salazaralorena papeldelospolimorfismos238y308delpromotordelfactordenecrosistumoralalfaenlapatogeniayrespuestaaltratamientoantifactordenecrosistumoralalfaenartritisreumatoide AT aguillongjuanc papeldelospolimorfismos238y308delpromotordelfactordenecrosistumoralalfaenlapatogeniayrespuestaaltratamientoantifactordenecrosistumoralalfaenartritisreumatoide AT cuchacovichtmiguel papeldelospolimorfismos238y308delpromotordelfactordenecrosistumoralalfaenlapatogeniayrespuestaaltratamientoantifactordenecrosistumoralalfaenartritisreumatoide
_version_	1718436224621871104

Papel de los polimorfismos -238 y -308 del promotor del factor de necrosis tumoral alfa en la patogenia y respuesta al tratamiento anti- factor de necrosis tumoral alfa en artritis reumatoide

Ejemplares similares